Join our daily newsletter At The Bell to receive exclusive market insights
OncoSil Medical (ASX:OSL), in its ongoing mission to develop treatments for pancreatic cancer, says the first patient treatment using the OncoSilTM device for its TRIPP-FXX clinical study has been conducted at the prestigious Hammersmith Hospital in London.
The OncoSilTM device, designed to target pancreatic cancer, marks a significant step forward in the fight against this disease. The TRIPP-FXX clinical study aims to evaluate the safety and effectiveness of the OncoSilTM device when used alongside standard FOLFIRINOX chemotherapy for treating locally advanced pancreatic cancer. This study, spanning multiple countries including Spain, the UK, Australia, Italy, and Belgium, demonstrates the global reach and significance of OncoSil’s innovative approach to cancer treatment. Currently, 11 sites are actively recruiting patients, with 29 patients already enrolled in the study.
OncoSil Medical CEO & Managing Director Nigel Lange said this validated the perception that the company was successfully executing on two broad-based components of its growth strategy.
“The first of these is to continue research of the OncoSilTM device through continued clinical studies and the second is to commercialise the device in several key target markets including Western Europe and the UK,” he said.
OSL has been trading at 0.6 cents.
